Bayer AG (XSWX:BAYN) 5-Year EBITDA Growth Rate: 0.00% (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XSWX:BAYN Bayer AG XSWX:BAYN
45 GF Score
Price CHF46.44
GF Value CHF24.68
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is Bayer AG 5-Year EBITDA Growth Rate?

Bayer AG XSWX:BAYN -1.94% 45 5-Year EBITDA Growth Rate is 0.00% as of Mar. 2026. GuruFocus rates XSWX:BAYN with a GF Score™ of 45/100 and a GF Value™ of CHF24.68 (Significantly Overvalued). The stock has 7 warning signs investors should review.

Bayer AG's EBITDA per Share for the three months ended in Mar. 2026 was CHF4.37.

During the past 12 months, Bayer AG's average EBITDA Per Share Growth Rate was -62.10% per year. During the past 3 years, the average EBITDA Per Share Growth Rate was -47.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Bayer AG was 15.40% per year. The lowest was -47.20% per year. And the median was 2.70% per year.

Bayer AG  (XSWX:BAYN) 5-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

5-Year EBITDA Growth Rate gives an overview of the company's growth in operating profitability and is an important factor used in calculating Peter Lynch Fair Value.

Bayer AG 5-Year EBITDA Growth Rate Related Terms

XSWX:BAYN vs LLY, JNJ, ABBV: 5-Year EBITDA Growth Rate Comparison

For the Drug Manufacturers - General subindustry, Bayer AG's 5-Year EBITDA Growth Rate, along with its competitors' market caps and 5-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Bayer AG 5-Year EBITDA Growth Rate vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Bayer AG's 5-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where Bayer AG's 5-Year EBITDA Growth Rate falls into.


XSWX:BAYN
45GF Score
Bayer AG XSWX:BAYN
5-Year EBITDA Growth Rate is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Bayer AG 5-Year EBITDA Growth Rate Calculation

This is the 5-year average growth rate of EBITDA per Share. The growth rate is calculated with least square regression.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

What does a 5-Year EBITDA Growth Rate of 0.00% mean?
Bayer AG (XSWX:BAYN) has a 5-Year EBITDA Growth Rate of 0.00% as of Mar. 2026. 5-Year EBITDA Growth Rate is the 5-year average growth rate of EBITDA per share. View historical data for Bayer AG and its competitors.
Is Bayer AG's 5-Year EBITDA Growth Rate too high?
Bayer AG's current 5-Year EBITDA Growth Rate is 0.00%. Overall, Bayer AG has a GF Score™ of 45/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Bayer AG's 5-Year EBITDA Growth Rate compare to LLY and JNJ?
Bayer AG's 5-Year EBITDA Growth Rate of 0.00% can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year EBITDA Growth Rate for a Drug Manufacturers company?
A good 5-Year EBITDA Growth Rate depends on the Drug Manufacturers industry context. However, 5-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year EBITDA Growth Rate mean?
A high 5-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 5-Year EBITDA Growth Rate is the 5-year average growth rate of EBITDA per share. View historical data for Bayer AG and its competitors. Bayer AG's current 5-Year EBITDA Growth Rate is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bayer AG stock overvalued right now?
Based on GuruFocus' analysis, Bayer AG (XSWX:BAYN) is currently considered Significantly Overvalued. The stock's GF Value™ is CHF24.68, compared to a current price of CHF46.44 — trading 88.2% above its estimated fair value. The current 5-Year EBITDA Growth Rate is 0.00%. Bayer AG's overall GF Score™ is 45/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year EBITDA Growth Rate calculated?
5-Year EBITDA Growth Rate is calculated from a company's financial statements. For Bayer AG (XSWX:BAYN), the current 5-Year EBITDA Growth Rate is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Bayer AG (XSWX:BAYN) Overvalued in 2026?

Based on GuruFocus' analysis, Bayer AG stock appears to be overvalued. The current stock price of CHF46.44 is trading 88.2% above its estimated GF Value™ of CHF24.68. GuruFocus considers Bayer AG to be Significantly Overvalued.

Key valuation signals for XSWX:BAYN:

  • 5-Year EBITDA Growth Rate: 0.00%
  • GF Value™: CHF24.68 vs. price of CHF46.44 (88.2% above fair value)
  • GF Score™: 45/100 with 7 warning signs

No single metric tells the full story. See the XSWX:BAYN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Bayer AG Business Description

Address Kaiser-Wilhelm-Allee 1, Leverkusen, NW, DEU, 51368
Bayer is a German healthcare and agriculture conglomerate. Healthcare provides close to half of the company's sales and includes pharmaceutical drugs (about 38% of total sales in 2025) as well as vitamins and other consumer healthcare products (13% of total). The firm's crop science business (47% of total) sells seeds, pesticides, herbicides, and fungicides, which was expanded through its 2018 acquisition of Monsanto.
45GF Score

Get the complete analysis for XSWX:BAYN

5-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

CHF46.44
Price
CHF24.68
GF Value